icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Evaluation of Drug Interaction Potential of the HCV Protease Inhibitor Asunaprevir (ASV; BMS-650032) at 200 mg Twice Daily (BID) in Metabolic Cocktail and P-glycoprotein (P-gp) Probe Studies in Healthy Volunteers
 
 
  Reported by Jules Levin AASLD Nov 4-8 2011 SF
 
Eley T, Gardiner D, Persson A, He B, You X, Shah V, Sherman D, Kandoussi H, Sims K, Pasquinelli C, Bertz R
Chengdu, China; 25The Second Affiliated Hospital

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif